IL Chicago의 버킷 림프종 임상 시험
버킷 림프종 관련 연구 15개가 Chicago 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
피험자 모집 중1/2상
- Research Site, Chicago
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
피험자 모집 중1상
- Lurie Children's Hospital, Chicago
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
피험자 모집 중1상
- University of Chicago Comprehensive Cancer Center, Chicago
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
피험자 모집 중2상
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
피험자 모집 중3상
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- 외 1개
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
피험자 모집 중2상
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
피험자 모집 중2상
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
피험자 모집 중1/2상
- Research Site, Chicago
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
피험자 모집 중2상
- University of Chicago Comprehensive Cancer Center, Chicago
Blinatumomab Consolidation in Real World
피험자 모집 중관찰 연구건강한 지원자 환영
- Northwestern University, Chicago
- The University of Chicago, Chicago
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
피험자 모집 중3상
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
피험자 모집 중2상
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
피험자 모집 중1상
- University of Chicago Comprehensive Cancer Center, Chicago
Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
피험자 모집 중
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
다른 도시의 버킷 림프종 시험
- Houston, TX연구 20개
- Milwaukee, WI연구 16개
- Philadelphia, PA연구 15개
- Seattle, WA연구 14개
- Atlanta, GA연구 13개
- New York City, NY연구 13개
- Cincinnati, OH연구 13개
- Los Angeles, CA연구 10개
- Baldwin Park, CA연구 10개
- Aurora, CO연구 10개
- Durham, NC연구 10개
- Kansas City, MO연구 10개
Chicago의 다른 연구
- 유방암연구 59개
- 비소세포폐암연구 59개
- 암 (전체)연구 51개
- 전립선암연구 45개
- 폐암연구 43개
- 전이성 암연구 42개
- 비만연구 40개
- 난소암연구 36개
- 대장직장암연구 32개
- 뇌졸중연구 31개
- 두경부 편평세포암연구 29개
- 과체중연구 29개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.